RAD51 novel target EIF4A1 promotes colorectal cancer cell proliferation and migration via the CYP51A1/cholesterol metabolic homeostasis pathway

Colorectal cancer is a disease that begins in the lining of the large intestine, often growing from small, benign growths into aggressive tumors that can spread throughout the body. It remains one of the most common and deadly cancers worldwide, affecting millions of people every year. While doctors have many tools to fight it, including surgery and drugs, the disease is complex, and understanding exactly how cancer cells grow and move is essential for finding better ways to stop them. At the heart of this struggle is a fundamental biological process called protein production. Inside every cell, there are molecular machines that read genetic instructions and build proteins, which act as the workers and builders of life. One specific component of this machinery, a protein called EIF4A1, has been noticed in many types of cancer because it seems to be working overtime, helping tumors grow faster. Scientists have long suspected that this protein plays a role in colorectal cancer, but they did not know exactly how it did its work or what other molecules it might be controlling to make the disease so dangerous.

A team of researchers at Yan'an University in China set out to uncover the hidden steps this protein takes to drive colorectal cancer forward. They started by looking at cancer cells in a laboratory dish, specifically using two common types of colorectal cancer cells known as RKO and HCT-116. To see what happens when the cancer loses its helper, the scientists used a precise tool to turn down the activity of the EIF4A1 protein, essentially silencing it within the cells. They then watched what happened to the cells' behavior. The results were clear: without this protein, the cancer cells stopped growing as fast and lost their ability to move around and spread. When the researchers measured the cells' ability to multiply, they found that the silenced cells formed far fewer new colonies than the healthy, active ones. Similarly, tests designed to see how well the cells could migrate showed that the silenced cells were much slower and less able to cross barriers, a key step in cancer spreading to other parts of the body. This confirmed that EIF4A1 is a powerful engine for the cancer's growth and movement.

But the researchers wanted to know why. They suspected that EIF4A1 was not acting alone but was instead controlling a specific metabolic process inside the cell. They focused on cholesterol, a waxy substance that is vital for building cell membranes and is often in high demand by rapidly dividing cancer cells. By analyzing the cells after they silenced EIF4A1, the team discovered that the total amount of cholesterol inside the cancer cells dropped significantly. The cells also changed how they handled cholesterol: they stopped making as much of it, stopped taking it in from their surroundings, and started pushing more of it out. This suggested that EIF4A1 normally keeps the cholesterol levels high, which in turn fuels the cancer's rapid expansion. The scientists then traced this effect to a specific enzyme called CYP51A1, which acts like a gatekeeper in the pathway that creates cholesterol. They found that when EIF4A1 was silenced, the levels of this enzyme fell, and the cholesterol production line slowed down. To prove that CYP51A1 was the missing link, the researchers added a dose of the enzyme back into the silenced cells. This simple act restored the cholesterol levels and brought the cancer cells' ability to grow and move back to normal, showing that EIF4A1 works by keeping CYP51A1 active.

The story did not end there, as the team wanted to understand what was turning on EIF4A1 in the first place. They looked for a master switch, a molecule that could be telling EIF4A1 to work so hard. Their investigation pointed to another protein called RAD51, which is known for its role in fixing damaged DNA but is also found in high amounts in many cancers. The researchers found that when they silenced RAD51, the levels of EIF4A1 dropped along with it. To confirm that RAD51 was directly controlling EIF4A1, they looked at the genetic instructions for EIF4A1 and found a specific spot where RAD51 could attach itself, acting like a switch to turn the gene on. This revealed a chain of command: RAD51 sits at the top, activating EIF4A1, which then boosts CYP51A1, leading to high cholesterol levels that allow the cancer cells to multiply and spread.

This study maps out a clear path of cause and effect in colorectal cancer, showing how a single protein can drive a disease by manipulating the cell's energy and building materials. The researchers demonstrated that EIF4A1 is not just a bystander but a critical driver that relies on cholesterol metabolism to fuel tumor growth, and that this entire process is set in motion by the activity of RAD51. While this work was conducted in a laboratory setting and does not yet represent a new treatment for patients, it identifies specific targets that could be useful for future therapies. By understanding that blocking EIF4A1 or its upstream activator RAD51 could disrupt the cholesterol supply that cancer cells need, scientists now have a clearer picture of where to aim their efforts to stop colorectal cancer in its tracks. The findings suggest that interrupting this specific chain of events could offer a new way to slow down or halt the progression of the disease, providing a fresh perspective for researchers working to improve outcomes for those affected.